**Question:** Low molecular weight heparin inhibits

A. Factor Xa
B. Factor IIa
C. Antithrombin III
D. Platelet aggregation

**Core Concept:** Low molecular weight heparins (LMWHs) are a type of anticoagulant medication used to prevent and treat blood clots. They are derived from unfractionated heparin (UFH) and have a smaller molecular weight, allowing for easier absorption and less frequent dosing. The primary mechanism of action involves inhibiting specific enzymes in the coagulation cascade.

**Why the Correct Answer is Right:** Low molecular weight heparin inhibits Factor Xa (coagulation enzyme). This is important because Factor Xa plays a crucial role in the common pathway of the coagulation cascade, converting prothrombin to thrombin. By inhibiting Factor Xa, LMWH reduces thrombin formation and subsequently prevents blood clot formation and growth.

**Why Each Wrong Option is Incorrect:**

A. Factor IIa (thrombin) is incorrect because it is not inhibited by low molecular weight heparin. Factor IIa is involved in the common pathway of coagulation, where it converts fibrinogen to fibrin. However, LMWH does not inhibit this enzyme, thus its inhibition is not the primary mechanism of action for LMWH.

B. Antithrombin III is another incorrect option. Antithrombin III is an anticoagulant protein that inhibits Factor Xa and thrombin. However, LMWH primarily inhibits Factor Xa and does not significantly affect Antithrombin III.

C. Platelet aggregation is another incorrect option. Low molecular weight heparin primarily inhibits Factor Xa and thrombin, which are involved in blood clot formation, rather than affecting platelet aggregation directly.

**Clinical Pearl:** LMWH is a valuable tool in preventing and treating deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as stroke prophylaxis in high-risk patients. It is also used in managing certain types of cancer-related thrombosis and preventing cardiovascular events in patients with coronary artery disease.

**Correct Answer Explanation:** D. Factor Xa (coagulation enzyme)

Low molecular weight heparin inhibits Factor Xa, which is a key enzyme in the common pathway of the coagulation cascade. Factor Xa converts prothrombin to thrombin, which in turn activates fibrinogen to fibrin, leading to blood clot formation. By inhibiting Factor Xa, LMWH prevents the conversion of prothrombin to thrombin and subsequent fibrin formation, ultimately reducing blood clot formation and growth.

**Why Each Wrong Option is Incorrect:**

A. Factor IIa (thrombin) is incorrect because LMWH does not primarily target this enzyme. Factor IIa is involved in converting fibrinogen to fibrin, leading to blood clot formation. However, LMWH primarily inhibits Factor Xa, not Factor IIa.

B. Platelet aggregation is also incorrect. LMWH primarily targets clot formation through inhibition of Factor Xa and thrombin, not directly affecting platelet